Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report released on Friday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Trading Down 1.4 %

Shares of EGRX stock traded down $0.06 on Friday, reaching $4.09. 83,502 shares of the stock were exchanged, compared to its average volume of 192,976. The company has a market capitalization of $53.12 million, a price-to-earnings ratio of 3.47 and a beta of 0.51. The business’s 50 day moving average price is $4.86 and its 200 day moving average price is $5.01. Eagle Pharmaceuticals has a twelve month low of $3.21 and a twelve month high of $19.49.

Institutional Investors Weigh In On Eagle Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Headlands Technologies LLC lifted its position in Eagle Pharmaceuticals by 75.7% in the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock valued at $35,000 after acquiring an additional 2,861 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Eagle Pharmaceuticals by 623.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,841 shares of the specialty pharmaceutical company’s stock valued at $36,000 after purchasing an additional 5,896 shares during the period. DGS Capital Management LLC acquired a new stake in shares of Eagle Pharmaceuticals in the 4th quarter valued at about $60,000. Price T Rowe Associates Inc. MD purchased a new position in Eagle Pharmaceuticals during the 1st quarter worth approximately $83,000. Finally, Aristides Capital LLC acquired a new position in shares of Eagle Pharmaceuticals in the 4th quarter valued at $86,000. Institutional investors and hedge funds own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.